Phase III PlanB Final Analysis: Adjuvant TC vs EC→T in Pts With High-Risk HER2-Negative Early Breast Cancer
TRAIN-2 (BOOG 2012-03): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC
I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
Targeting CDK4/6 in Patients With Cancer
Combination Approaches and Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.